Cagrilintide and serotonin: what the evidence actually shows

What did @taylorreidcoachin actually say?

Honestly, less than the caption implies. The creator said she noticed something affecting her mood or energy while using cagrilintide, noted it, adjusted, and moved on. She said it "wasn't a big deal." The caption, however, introduces the phrase "serotonin DUMP" and claims amylin analogs interact with brain regions that control serotonin. That framing is doing a lot of heavy lifting the actual video does not support.

To her credit, she was measured in the transcript. She acknowledged uncertainty, said she "didn't think it was going to affect my serotonin levels," and framed it as personal observation rather than established mechanism. That is a meaningful distinction from the caption's more assertive clinical language.

The problem is that most viewers read captions, not transcripts. The gap between "I noticed something and adjusted" and "serotonin DUMP" is significant enough to warrant examination.

Does the science back this up?

Partially, but not in the way the caption suggests. Amylin receptors are expressed in brain regions including the area postrema, nucleus accumbens, and brainstem, areas involved in appetite, reward, and to some degree mood regulation. There is no peer-reviewed evidence that cagrilintide specifically triggers a "serotonin dump" in humans.

What we do know: amylin signaling has been studied in rodent models in relation to dopamine and reward pathways (Bhavya et al., 2022, Neuroscience and Biobehavioral Reviews), but the leap to serotonin disruption in women is not supported by current clinical trial data. The SCALE-NEXT trial for cagrilintide plus semaglutide (CagriSema) reported nausea and fatigue as common adverse events, but these were not attributed to serotonergic mechanisms. Fatigue and low mood can have many explanations during caloric restriction or medication initiation, including hypoglycemia, nausea-related sleep disruption, or simple adjustment effects.

Attributing those symptoms specifically to serotonin, and specifically in women, is a speculative claim that currently lacks clinical citation.

What did they get wrong (or right)?

Right: cagrilintide is worth being mindful of. It is an investigational amylin analog, and amylin receptor activity in the brain is real. The creator is correct that amylin analogs are not pharmacologically identical to GLP-1 receptor agonists, so prior tolerance to GLP-1s does not predict full tolerance to cagrilintide. That is actually a reasonable thing to flag.

Wrong: the caption's "serotonin DUMP" framing has no mechanistic evidence behind it. Serotonin is not the primary neurotransmitter associated with amylin receptor activity. Dopamine and norepinephrine pathways are more frequently implicated in amylin's central effects in preclinical literature (Bhavya et al., 2022). Presenting a personal anecdote of fatigue or low mood as a serotonin event, without measurement or clinical diagnosis, is a leap. There are no studies measuring serum or synaptic serotonin changes in humans following cagrilintide administration.

The creator also appears to be using cagrilintide outside of an approved clinical context, as it has no current FDA approval for standalone use. That deserves more than a passing mention.

What should you actually know?

Cagrilintide is still in clinical development. As of 2024, it is being studied primarily in combination with semaglutide as CagriSema (Novo Nordisk), with Phase 3 data showing meaningful weight reduction but no approved label. Using it outside of a clinical trial or regulated prescribing context means no established dosing protocol, no pharmacovigilance reporting structure, and no standardized safety monitoring.

If you experience mood changes, fatigue, or energy shifts after starting any peptide or medication, those symptoms deserve evaluation by a clinician, not self-diagnosis via serotonin theory. Mood changes during weight loss interventions are common and multifactorial. A study by Kolotkin et al. (2017, Obesity Reviews) found that psychological wellbeing during weight loss is influenced by dietary restriction, sleep quality, and hormonal changes, not just the pharmacological agent itself.

The responsible takeaway from this video is the creator's own words: note it, adjust, consult someone. Not "this peptide depletes your serotonin."